期刊文献+

^(18)F-FDG符合线路显像与^(99m)Tc-MDP骨显像及二者联合对乳腺癌骨转移的检出效能 被引量:4

^(18)F-FDG SPECT coincidence,^(99m)Tc-MDP bone scintigraphy and combination of the two techniques for detecting malignant bone metastasis from breast cancer
下载PDF
导出
摘要 目的采用ROC曲线比较18F-FDG符合线路显像、99mTc-MDP骨显像及二者联合对乳腺癌骨转移的检出效能。方法收集手术病理诊断为乳腺癌的女性患者113例,均于4周内先后接受18 F-FDG符合线路显像及99mTc-MDP骨显像;对两种显像结果按5分法评分,以二者评分之和为联合评分值,以病理诊断或临床随访为确诊"金标准",比较ROC曲线下面积(AUC),评价99mTc-MDP骨显像、18F-FDG符合线路显像及联合评分法对乳腺癌骨转移患者的检出效能,比较不同方法在各自最佳诊断阈值下的灵敏度、特异度、准确率、阳性预测值(PPV)和阴性预测值(NPV)。结果113例中,12例(10.62%)最终确诊为骨转移,101例(89.38%)无骨转移。99mTc-MDP骨显像、18F-FDG符合线路显像以及二者联合诊断评分的ROC曲线分析显示三者AUC分别为0.991、0.874和0.993,三种方法对乳腺癌骨转移的诊断效能均佳,尤以99mTc-MDP骨显像与联合诊断为最佳(P均<0.01)。最佳阈值点下,单独18F-FDG符合线路显像、99mTc-MDP骨显像及联合检出骨转移患者的灵敏度分别为75.00%(9/12)、75.00%(9/12)、83.33%(10/12),特异度为100%(101/101)、98.02%(99/101)、98.02%(99/101),准确率为97.35%(110/113)、95.58%(108/113)、96.46%(109/113),PPV为100%(9/9)、81.82%(9/11)、83.33%(10/12),NPV为97.12%(101/104)、97.06%(99/102)、98.02%(99/101)。结论 99mTc-MDP骨显像对乳腺癌骨转移患者的检出效能优于18F-FDG符合线路显像,二者联合可提高对骨转移患者的检出率。 Objective To observe the efficacy of ^18F_FDG SPECT coincidence (^18F-FDG SPECT), ^99mTc-MDP bone scin- tigraphy (BS) and combination of the two techniques (^18 F-FDG SPECT+^99mTc-MDP BS) for detecting bone metastasis from breast cancer by ROC curve analysis. Methods Totally 113 patients with breast cancer underwent both ^99mTc-MDP BS and ^18F-FDG SPECT within 4 weeks. The images were interpreted according to 5-point scale, and the scale of ^18 F-FDG SPECT+^99mTc-MDP BS was the sum of ^18 F-FDG SPECT plus ^99mTc-MDP BS. The final diagnosis of bone metastases was established by pathology or follow-up, and then ROC curve analysis was performed. The area under the curve (AUC), the sensitivity, specificity, accuracy rate, positive predictive value (PPV), negative predictive value (NPV) of cut-off point were compared. Results Of 113 cases, 12 (12/113, 10. 62%) were finally confirmed as bone metastases, while 101 (101/ 113, 89.38%) were negative. The AUC was 0. 991 for 99mTc-MDP BS, 0. 874 for ^18F-FDG SPECT, and 0. 993 for ^18F- FDG SPECT+^99mTc-MDP BS, respectively. AUC of ^99mTc-MDP BS and ^18F-FDG SPECT+^99mTc-MDP BS were signifi- cantly larger than that of ^18 F-FDG SPECT (all P〈0. 01). The optimal sensitivity of ^18 F-FDG SPECT,^ 99m Tc-MDP BS and ^18F-FDG SPECT+^99mTc-MDP BS was 75.00% (9/12), 75.00% (9/12) and 83. 33% (10/12), respectively, the specifici- ty was 100% (101/101), 98.02% (99/101) and 98.02% (99/101), respectively , the accuracy rate was 97.35% (110/ 113), 95.58% (108/113) and 96.46% (109/113), respectively , while PPV was 100% (9/9), 81.82% (9/11), 83.33% (10/12) and NPV was 97.12% (101/104), 97.06% (99/102) and 98.02% (99/101), respectively. Conclusion The effi- cacy of ^99mTc-MDP BS for detecting malignant bone metastasis was superior to that of ^18 F-FDG SPECT alone. The detec- tion ability can be obviously improved by combination of these two techniques.
出处 《中国医学影像技术》 CSCD 北大核心 2012年第12期2175-2179,共5页 Chinese Journal of Medical Imaging Technology
关键词 乳腺肿瘤 肿瘤转移 放射性核素显像 18F氟脱氧葡萄糖 99m锝亚甲基二磷酸 Breast neoplasms Neoplasm metastasis Radionuclide imaging Fluorodeoxyglucose F18 Technetium Tc99m medronate
  • 相关文献

参考文献4

二级参考文献40

  • 1付占立,林景辉,张春丽,胡怀湘,范岩,王荣福.^(18)F-FDG符合线路显像在骨及软组织肿瘤复发中的诊断价值[J].中国医学影像技术,2004,20(10):1487-1489. 被引量:3
  • 2刘颖新,朱小东.PET-CT在确定非小细胞肺癌放疗靶区中的应用[J].肿瘤学杂志,2007,13(1):19-21. 被引量:1
  • 3Penny F Whiting,Marie E Weswood,Anne WS Rutjes,Johannes B Reitsma,Patrick NM Bossuyt,Jos Kleijnen,马章淳,钱楠.QUADAS评价:一种用于诊断性研究的质量评价工具(修订版)[J].中国循证医学杂志,2007,7(7):531-536. 被引量:65
  • 4Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol, 1998, 16(10): 3375- 3379. 被引量:1
  • 5Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol, 2006, 6: 9. 被引量:1
  • 6Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol, 2002, 2: 9. 被引量:1
  • 7Kruger S, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging, 2009, 36(11): 1807-1812. 被引量:1
  • 8Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/ CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci, 2009, 24(2): 275-280. 被引量:1
  • 9Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F- fluoride PET, and 18F-fluoride PET/CT. J Nucl Med, 2006, 47(2): 287-297. 被引量:1
  • 10Song JW, Oh YM, Shim TS, et al. Efficacy comparison between (18) F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer, 2009, 65(3): 333-338. 被引量:1

共引文献17

同被引文献35

  • 1刘青竹,范义湘,吴继珍,高梅菊,李科斌.^(18)F-FDG SPECT/PET代谢显像对肺癌的诊断价值[J].肿瘤学杂志,2009,15(12):1060-1062. 被引量:6
  • 2张春银,吴天革,刘科,陈跃,黄占文,张艳玲.^(18)F-FDG符合线路SPECT显像在乳腺癌的临床应用[J].中国医学影像技术,2006,22(6):938-940. 被引量:5
  • 3韩丽君.PET/CT在乳腺癌中的临床应用[J].中国医疗器械信息,2006,12(10):10-15. 被引量:4
  • 4Jemal A, Siegel, Ward E, et al. Cancer statistics [ J ]. CA Cancer J Clin,2008 ,58 :71-96. 被引量:1
  • 5Van Dongen JA, Voogd AC, Fentiman IS, et al. Long term results of a randomized trial comparing breast-eonserving therapy with mas- tectomy: European Organization for Re-search and Treatment of Cancer[J]. J Natl Cancer lnst, 2000,92(14) :1143-1150. 被引量:1
  • 6Yap CS, Seltzer MA, Schiepers C, et al. Impact of whole-body is F-FDG PET on staging and managing patients with breast cancer: the referring physician' sperspective [ J ]. J Nucl Med, 2001,42 (9) :1334-1337. 被引量:1
  • 7Dirisamer A, Halpem BS, Flory D, et al. Integrated contrast-en- hanced diagnostic whole-body PET/CT as a first-line restaging mo- dality in patients with suspected metastatic re-currence of breast cancer[J]. Eur J Radiol, 2010,73(2) :294-299. 被引量:1
  • 8Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her-2-positive breast cancer[ J ]. N EngI J Med, 2005,352(16) :1659-1663. 被引量:1
  • 9Gago FE,Fanelli MA, Ciocca DR, et al. Co-expression of steroid hormone receptors( estrogen receptoralpha and/or progesterone re- ceptors) and Her-2-neu in breast cancer: Clinical outcome following tamoxifen-based adjuvanttherapy[ J]. J Steroid Biochem Mol Biol, 2006,98 ( 1 ) :36-39. 被引量:1
  • 10Pinto AE,Andre S, Pereira T, et al. C-erbB-2 oncopretein overex- pression identifiers a subgroup of estrogen receptor positive( ER + ) breast cancer patients with poor prognosis[J]. Ann Oncol, 2001, 12(4) :525-528. 被引量:1

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部